Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404748 | 0.95 | NOD1 (0.47) | NOD1PTGS1GSTK1GNPATFNTA | |
| SCHEMBL29880339 | 0.93 | NOD1 (0.44) | NOD1PTGS1GSTK1GNPATFOLH1 | |
| SCHEMBL30140821 | 0.93 | NOD1 (0.50) | NOD1PTGS1GSTK1GNPATFNTA | |
| SCHEMBL27632323 | 0.93 | NOD1 (0.51) | NOD1PTGS1GSTK1FNTAFNTB | |
| SCHEMBL27632326 | 0.93 | NOD1 (0.51) | NOD1PTGS1GSTK1FNTAFNTB | |
| SCHEMBL30943802 | 0.92 | NOD1 (0.43) | NOD1PTGS1GSTK1FOLH1EPHX2 | |
| SCHEMBL10651108 | 0.91 | NOD1 (0.41) | NOD1PTGS1GSTK1GLO1NPY1R | |
| SCHEMBL29630329 | 0.90 | NOD1 (0.49) | NOD1PTGS1GSTK1FNTAFNTB | |
| SCHEMBL30414136 | 0.90 | NOD1 (0.52) | NOD1PTGS1GSTK1GNPATFNTA | |
| SCHEMBL32684785 | 0.90 | NOD1 (0.49) | NOD1PTGS1GSTK1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472262-B2 | Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects | FRIEDRICH-SCHILLER-UNIVERSITAET JENA (DE) | 2025-11-18 | — | — | US | claimed |
| US-20220241426-A1 | PEPTIDE FOR USE IN THE REDUCTION OF SIDE EFFECTS IN THE FORM OF IMMUNOSTIMULATORY REACTIONS/EFFECTS | UNIV JENA FRIEDRICH SCHILLER (DE) | 2022-08-04 | — | — | US | claimed |
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | EXUMA BIOTECH CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-12540349-B2 | Horseshoe crab factor B variant | SEIKAGAKU CORPORATION (JP) | 2026-02-03 | — | — | US | disclosed |
| US-12472262-B2 | Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects | FRIEDRICH-SCHILLER-UNIVERSITAET JENA (DE) | 2025-11-18 | — | — | US | disclosed |
| US-20250346648-A1 | MAGE A4 T CELL RECEPTORS | MEDIGENE IMMUNOTHERAPIES GMBH (DE) | 2025-11-13 | — | — | US | disclosed |
| EP-4631516-A2 | MAGE A4 T CELL RECEPTORS | Medigene Immunotherapies GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| EP-3476402-B1 | CAPSULE FOR DRUG DELIVERY SYSTEMS OF TARGET TISSUE-SPECIFIC DELIVERY TYPE USING CARBOSILANE DENDRIMER | UNIV SAITAMA (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12344654-B2 | Mage A4 T cell receptors | MEDIGENE IMMUNOTHERAPIES GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20250195626-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LTD (GB) | 2025-06-19 | — | — | US | disclosed |
| WO-2022208091-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022197693-A2 | SYSTEM OF STABLE GENE EXPRESSION IN CELL LINES AND METHODS OF MAKING AND USING THE SAME | 490 BioTech, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220275324-A1 | STENOTROPHOMONAS MALTOPHILIA GYH AND APPLICATION THEREOF IN DEGRADATION OF CHLORINATED HYDROCARBON POLLUTANTS | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2022-09-01 | — | — | US | disclosed |
| US-20220241426-A1 | PEPTIDE FOR USE IN THE REDUCTION OF SIDE EFFECTS IN THE FORM OF IMMUNOSTIMULATORY REACTIONS/EFFECTS | UNIV JENA FRIEDRICH SCHILLER (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220211823-A1 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | IPSEN BIOPHARM LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| WO-2022090716-A1 | POLYPEPTIDES FOR CANCER TREATMENT | Oxford Vacmedix UK Limited (GB) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090679-A1 | CORONAVIRUS POLYPEPTIDE | Oxford Vacmedix UK Limited (GB) | 2022-05-05 | — | — | WO | disclosed |
| CN-114126716-A | MAGE A4T cell receptor | 基因医疗免疫疗法有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022034498-A1 | MOVING-FRONT STERILIZATION MONITORING DEVICES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540349-B2 | Horseshoe crab factor B variant | RNGTT, UPF1, F13B | NOD1 314/4885PTGS1 1788/4885GSTK1 828/4885 |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | NOD1 699/4885PTGS1 3031/4885GSTK1 2239/4885 |
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | CD4, PBK, CD69 | NOD1 2083/4885PTGS1 4162/4885GSTK1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.